Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urothelial Cancer 1Squamous Cell Carcinoma of Head and Neck 1Spinocerebellar Degenerations 1Small Cell Lung Carcinoma 1Sarcoma 1Rhabdoid Tumor 1Rectal Neoplasms 1Neoplasms 1Lung Neoplasms 1Esophageal Squamous Cell Carcinoma 1Colorectal Neoplasms 1Chordoma 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Advanced Solid Malignancies 1Advanced Rare Malignant Solid Neoplasm 1

Interventions

pembrolizumab 30Nivolumab 29cabozantinib 19Ipilimumab 15Magnetic Resonance Spectroscopy 14belzutifan 13lenvatinib 11Axitinib 9Specimen Handling 8Sunitinib 7durvalumab 5CTLA-4 Antigen 5tislelizumab 4atezolizumab 4Radiosurgery 4Interleukin-2 4Everolimus 4Biopsy 4Bevacizumab 4pazopanib 3avelumab 3aldesleukin 3Immunoglobulin G 3Disulfides 3palbociclib 2fludarabine 2entinostat 2adavosertib 2Surveys and Questionnaires 2Paclitaxel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Carcinoma, Renal Cell × Tiragolumab × Clear all
NCT05805501 2026-05-12

A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

Hoffmann-La Roche

Phase 2 Active not recruiting
199 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡